Centerview Hires Merrill Healthcare Bankers

Centerview Partners has hired three Merrill Lynch investment bankers focused on the healthcare space: Alan Hartman, Richard Girling and Mark Robinson. The firm also announced that it opening new offices in London and San Francisco.

 

PRESS RELEASE

Centerview Partners announced that Alan Hartman, Richard Girling and Mark Robinson, three leading investment bankers specializing in the healthcare sector, have agreed to join the firm as partners to build its healthcare practice. Additionally, the firm is announcing that it will be opening an office in London and is also expanding its presence on the West Coast with an additional office to be opened in San Francisco.

 

Messrs. Hartman, Girling and Robinson have worked together for over a decade at Merrill Lynch & Co. and collectively have advised many of the most important transactions in the healthcare industry. Their relationships have been based upon providing strategic mergers and acquisitions advice to some of the biggest companies in the global pharmaceutical, biotechnology, medical device and healthcare services industries. Mr. Hartman has been Merrill’s Head of Americas Mergers & Acquisitions and Mr. Girling and Mr. Robinson have been Global Co-Heads of Merrill’s Healthcare Investment Banking group. Mr. Hartman will be based in New York while Mr. Girling and Mr. Robinson will be senior partners in the London and San Francisco offices, respectively.

 

“Our goal as a firm is to be a leader in providing high level strategic advice to world class companies across the most important business sectors globally,” said Blair Effron, a founding partner at Centerview Partners. “Alan, Richard and Mark are recognized as among the very top bankers in healthcare, bringing Centerview one step closer to achieving our goal.”

 

Collectively Messrs. Girling, Hartman and Robinson have advised on some of the industry’s landmark transactions including Pfizer’s $68 billion pending acquisition of Wyeth, Sanofi-Synthelabo’s $63 billion acquisition of Aventis, the $25 billion leveraged buyout of Alliance Boots plc, Astra Zeneca’s $15 billion acquisition of MedImmune, IDEC in its $6 billion merger with Biogen and Boston Scientific’s $25 billion acquisition of Guidant.

 

“Having Alan, Richard and Mark on our team is a milestone step in our firm’s evolution. Our mission as a firm is to attract the best banking talent, give them the resources to compete on a global basis, and have superior intellectual capital to assist clients on their most complex and challenging issues and opportunities,” said Robert Pruzan, a founding partner at Centerview Partners. “Opening London and San Francisco with these senior leaders is a natural next move for Centerview.”

 

“A hallmark of our firm is to carefully build a culture of partnership and excellence,” said Adam Chinn, a founding partner at Centerview Partners. “We’re pleased that Alan, Richard and Mark have worked together as partners for 10 years and share our vision.”

 

Since its founding in 2006, Centerview Partners has built a reputation as a trusted advisor to a wide range of publicly traded and privately owned companies and has been involved in some of the most complex and important transactions over the past three years. Selected transactions include the combined spin-offs of Kraft and Phillip Morris International from Altria, the $5.6 billion acquisition of Dow Jones by News Corp. and InBev’s $52 billion acquisition of Anheuser-Busch. Since its founding, the firm has executed over $250 billion in transactions across a broad range of industries.

 

“We are pleased to be adding healthcare sector expertise to the growing number of strategic sectors where we have deep advisory experience,” said Steve Crawford, a founding partner at Centerview Partners. “This complements a range of industries in which we have experience, including companies in the consumer, retail, financial institutions, media and entertainment, technology and general industrial sectors.”

 

About Alan Hartman

 

Alan Hartman joins Centerview Partners from Merrill Lynch where he has been in the mergers and acquisitions group for the past 15 years, most recently as Head of Americas M&A and Global Head of Healthcare M&A. Following the acquisition by Bank of America, he was appointed Head of Americas M&A for the combined organization.

 

Over the course of his career, Mr. Hartman has advised more than $250 billion of transactions including: Pfizer in its $68 billion pending acquisition of Wyeth, the $33 billion LBO of HCA, Celgene in its $2.9 billion acquisition of Pharmion, Boston Scientific in its $25 billion acquisition of Guidant, Bergen Brunswig in its $3.7 billion merger with Amerisource, Mylan in its $6.7 billion acquisition of Merck Generics, Biogen IDEC in its proxy contest with Carl Icahn and Ventas in its $2bn acquisition of Sunrise REIT.

 

Before joining Merrill Lynch in 1993, Mr. Hartman spent four years as a mergers and acquisitions attorney at Skadden, Arps, Meagher & Flom LLP in New York. He received a B.S. from the Wharton School of the University of Pennsylvania and a J.D. from Harvard Law School.

 

About Richard Girling

 

Richard Girling joins Centerview Partners from Merrill Lynch in London where he established that firm’s European healthcare effort in 1998, and has been a Global Co-Head of Healthcare investment banking for the past six years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization.

 

During his time at Merrill, Mr. Girling has advised on many of the largest healthcare transactions in Europe and Asia including: Sanofi-Synthelabo’s $63 billion acquisition of Aventis, the $25 billion LBO of Alliance Boots plc, AstraZeneca in its $15 billion acquisition of MedImmune, Mayne Pharma’s $2 billion sale to Hospira, Alliance Unichem in its $12 billion merger with Boots, CSL in its pending $3.1bn acquisition of Talecris as well as its acquisition of Aventis Behring, and numerous transactions for Roche.

 

Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

 

About Mark Robinson

 

Mark Robinson joins Centerview Partners from Merrill Lynch in San Francisco where he has led the firm’s America‘s Healthcare investment banking group, and has been a Global Co-Head for the past 6 years. Following the acquisition by Bank of America, he was appointed Co-Head of Americas Healthcare investment banking. Mr. Robinson came to Merrill Lynch in 1998 after working for five years at CS First Boston and Robertson Stephens.

 

Over the last 16 years, Mr. Robinson advised many of the leading biotechnology and medical device companies on more than 125 transactions totaling approximately $200 billion including: Gilead in its $1.3 billion pending acquisition of CV Therapeutics, Icos in its $2.4 billion sale to Eli Lilly, Immunex in its $17 billion sale to Amgen, IDEC in its $6 billion merger with Biogen, Vertex in numerous transactions, PDL Biopharma in its activist defense and restructuring, and Boston Scientific in its $25 billion acquisition of Guidant.

 

Mr. Robinson received his B.A. from the University of California Berkeley and an M.B.A. from Harvard University.

 

About Centerview Partners

 

Centerview Partners, based in New York, operates an investment banking advisory practice and a private equity business. The advisory business specializes in independent advice and other client services capitalizing on the experience of its principals. The firm provides senior-level counsel to both domestic and international clients. Members of the firm have experience in a range of industries including the consumer products, financial services, food and beverage, entertainment and media, healthcare, technology, general industrial and retail sectors. The private equity business has an operational excellence focus and targets its investments in consumer-oriented industries.